

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: William James Rae, M.D.  
and Bertie B. Griffiths, Ph.D.

Attorney Docket: 16715CIP

For: **AUTOGENOUS LYMPHOCYTIC FACTOR FOR MODIFICATION  
OF T AND B LYMPHOCYTE PARAMETERS**

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY  
STATUS (37 CFR 1.9(f) and 1.27(b)) -- INDEPENDENT INVENTORS**

As the below named inventors, we hereby declare that we qualify as independent inventors as defined in 37 CFR §1.9(c) for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code, to the Patent and Trademark Office with regard to the invention entitled **AUTOGENOUS LYMPHOCYTIC FACTOR FOR MODIFICATION OF T AND B LYMPHOCYTE PARAMETERS** described in the specification filed herewith.

We have not assigned, granted, conveyed, or licensed; and are under no obligation under contract or law to assign, grant, convey or license, any rights in the invention to any person who could not be classified as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern or organization to which we have assigned, granted, conveyed, or licensed or are under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below: no such person, concern, or organization

We acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate (37 CFR 1.28(b)).

We hereby declare that all statements made herein of our own knowledge are true, that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under §1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

DATE: \_\_\_\_\_

\_\_\_\_\_  
William James Rae, M.D.

Address: 4040 Beaverbrook  
Dallas, Texas 75229

Citizenship: U.S.A.

DATE: \_\_\_\_\_

\_\_\_\_\_  
Bertie B. Griffiths, Ph.D.

Address: 5602 Willowbrook Drive  
Rowlett, Texas 75088

Citizenship: U.S.A.

20250620 16:03:20

vblc\gimny\clients\ehod.3\smen

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: William James Rea, M.D.  
and Bertie B. Griffiths, Ph.D.

Attorney Docket No.: 16715CIP

For: **AUTOGENOUS LYMPHOCYTIC FACTOR FOR MODIFICATION  
OF T AND B LYMPHOCYTE PARAMETERS**

**DECLARATION FOR UTILITY PATENT APPLICATION**

Hon. Commissioner of Patents  
and Trademarks  
Box Applications  
Washington, D.C. 20231

Sir:

As the below named inventors, we hereby declare that:

Our residence, post office mailing address, and citizenship are as stated below next to our names.

We believe we are the original, first, and joint inventors of the subject matter which is claimed and for which a patent is sought on the invention entitled **AUTOGENOUS LYMPHOCYTIC FACTOR FOR MODIFICATION OF T AND B LYMPHOCYTE PARAMETERS**, the specification of which is attached hereto.

We hereby state that we have reviewed and understand the contents of the above-identified specification, including the claims.

We acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, § 1.56(a).

We hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed: International Patent Application Serial No. PCT/US96/01205, filed January 30, 1996 (designating and electing the United States), which was a continuation of U.S. Application Serial No. 08/380,063 filed January 30, 1995, now abandoned.

We hereby claim the benefit under Title 35, United States Code § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, we acknowledge the duty to disclose material information as

defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application: None

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

Inventor's signature:

Date: \_\_\_\_\_

\_\_\_\_\_  
William James Rea, M.D.  
Address: 4040 Beaverbrook  
Dallas, Texas 75229

Citizenship: U.S.A.

Inventor's signature:

Date: \_\_\_\_\_

\_\_\_\_\_  
Bertie B. Griffiths, Ph.D.  
Address: 5602 Willowbrook Drive  
Rowlett, Texas 75088

Citizenship: U.S.A.

26920680

vblc:\gimny\clients\ehod.3\ded